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Atrial ﬁbrillation (AF) imposes substantial burdens of morbidity and impaired health-
related quality of life, and signiﬁcantly increases suﬀerers’ risk of having a cardiovascular
event, in particular a stroke. Prevalence of AF in Asia and the associated healthcare costs are
likely to have been underestimated and are expected to increase due to greater awareness,
population ageing and increasing prevalence of associated risk factors and comorbidities.
The AF management paradigm is shifting from a conventional focus on achieving heart rate
or rhythm control, towards endeavouring to use the safest agents available to reduce patients’
symptoms and improve their quality of life and cardiovascular outcomes. No new anti-AF
drugs have been introduced for decades and existing pharmacotherapeutic modalities have
potentially serious side eﬀects as well as sub-optimal eﬃcacy in converting to and
maintaining normal sinus rhythm and preventing recurrence.
There is an unmet need for better anti-arrhythmic drugs that are well tolerated, eﬃcacious,
cost-eﬀective and have a more favourable safety proﬁle than current options. Although the
perfect agent remains to be discovered, some promising new anti-arrhythmic drugs have the
potential to overcome certain limitations of established approaches to AF management.
(J Arrhythmia 2011; 27: 171–185)
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Introduction
Atrial ﬁbrillation (AF) is a supraventricular
tachyarrhythmia characterised by uncoordinated
electrical activity of the atria.1) AF is the most
common sustained cardiac arrhythmia observed in
clinical practice; prevalence increases with age1) and
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AF may be either idiopathic, or associated with
structural heart disease and adverse cardiovascular
(CV) outcomes.
The epidemiology of AF and its potential inter-
actions with hypertension, diabetes, congestive heart
failure and stroke, rank AF among the top priorities
in cardiology and highlight the importance of
reﬁning management strategies to control this grow-
ing epidemic. To gain insights on AF management in
Asian patients, identify unmet needs and recommend
practical measures to improve clinical outcomes,
experts from Singapore and Malaysia convened to
review current practice and discuss emerging oppor-
tunities in AF care. This review encapsulates our
analysis of existing evidence and collective clinical
experience and our consensus view on best practices
in AF management. Our intention is not to establish
practice standards, but rather to provide useful
information that will help doctors in Asia to imple-
ment appropriate and eﬀective interventions that will
improve outcomes for their AF patients.
Epidemiology and burden of atrial ﬁbrillation
AF is an increasingly important healthcare issue,
particularly given the exponential worldwide growth
of the elderly population.2) Epidemiological data
consistently show that AF aﬀects twice many men as
women and is uncommon in people less than 60
years old, but increases markedly in prevalence
thereafter and aﬀects approximately 10% of 80 year
olds (Figure 1).3) In the Framingham Heart Study,
lifetime risk of AF was 25% in adults aged 40 years
and above;4) between 1968–70 and 1987–89, age-
adjusted prevalence of AF in the Framingham cohort
(age 65–84) increased from 3.2% to 9.1% in men
and from 2.8% to 4.7% in women;5) the number of
AF patients is projected to increase 2.5-fold over the
next 40 years.6)
AF has been reported to be slightly less prevalent
in Asians than Caucasians. Electrocardiograph
(ECG) documented AF prevalence in adults is
approximately 1.6% in Japan, 1.5% in Singapore,
0.7% in China, and 1.1% in Taiwan.7–10) Never-
theless, consistent with global trends, AF is the most
common signiﬁcant arrhythmia in Singapore and is
increasing rapidly due to population aging. In a study
of 1,839 Chinese residents aged 55 years or more,
the estimated prevalence of AF was 2.6% in men and
0.6% in women, increasing to 5.8% in adults aged
80 years and above.8) Physicians in Singapore and
Malaysia report that AF patient numbers have
increased by approximately 10% over the last 3
years,11) with further increases expected due to
population aging, increasing prevalence of comor-
bidities (e.g., diabetes, hypertension), and more
frequent referrals as awareness of AF increases.
AF causes multiple electrophysiological changes,
such as electrical, contractile, and structural remod-
elling of the atria.12) Patients with AF have a
signiﬁcantly higher prevalence of comorbidities
and concomitant CV risk factors than matched
controls, in particular, hypertension, dyslipidemia,
coronary heart disease, heart failure and diabe-
tes.13,14) AF doubles the risk of dying,15) increases
the likelihood of hospitalisation two- to three-
fold,16) and increases the risk of stroke by up to ﬁve
times.17) Stroke associated with AF is typically more
severe than that due to other causes18) and even
patients with less severely symptomatic or asympto-
matic AF are at increased risk. Survival rates for
complicated AF are worse than those of common
cancers. Moreover, AF adversely aﬀects quality of
life.19)
Figure 1 Prevalence of atrial ﬁbrillation in six
natural history studies
CHS: Cardiovascular Health Study, UK: United King-
dom, USA: United States of America
Gersh BJ, et al: The changing epidemiology of non-
valvular atrial ﬁbrillation: the role of novel risk factors.
European Heart Journal 2005; 7(Suppl C): C5–C11, by
permission of The European Society of Cardiology.
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Consequently, AF imposes a heavy burden on
healthcare systems worldwide.20–22) In the USA,
hospitalisations resulting from AF rose two- to three-
fold from 1985 to 1999.22) AF accounted for 2.8% of
1,435 acute admissions to Kuala Lumpur General
Hospital, Malaysia, over 4-weeks from May to June
2000.23) Similarly, almost 3% of 11,531 admissions
to the National Heart Centre, Singapore, from 1999
to 2001 were due to AF.24)
Current practice and emerging trends in the
management of atrial ﬁbrillation
Guidelines and terminology
In a cross-sectional survey of cardiologists, elec-
trophysiologists and internal medicine specialists
from Singapore and Malaysia with experience of
diagnosing and managing AF patients,11) most cited
guidelines from the American College of Cardiology
(ACC), American Heart Association (AHA), and
European Society of Cardiology (ESC) as the chief
inﬂuences on their treatment approach (Figure 2).25)
Accordingly, AF is usually classiﬁed as paroxysmal,
persistent, or permanent, depending on its pattern
of onset/recurrence and duration.11) Paroxysmal AF
denotes intermittent, self-terminating episodes, usu-
ally lasting less than 7 days, and aﬀects approx-
imately a quarter of AF patients in Singapore and
Malaysia. Sustained AF episodes (usually 1 week to
6 months) that do not revert to sinus rhythm without
medical intervention are termed persistent and
account for approximately 18% of the AF population
in Singapore and 34% in Malaysia. AF lasting for
more than 1 year is classiﬁed as permanent and
comprises the majority of diagnoses in Singapore
(56%) and Malaysia (40%).11)
Rate and rhythm control agents
The primary concern in AF management has
conventionally been choosing between rate-control
and rhythm-control strategies.26) Rate-control aims
to normalise the rapid ventricular rate in AF, without
attempting to restore or maintain sinus rhythm.1)
Optimum rate control usually requires ventricular
rate reduction both at rest and during activity.27)
Rates of 60 to 80 beats per minute (bpm) at rest and
90 to 115 bpm during ‘moderate’ exercise have been
proposed as adequate.1) Rate control is usually
accomplished by pharmacotherapy (Table 1),1,28)
with non-pharmacological therapy reserved for pa-
Figure 2 Therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent AF25)
LVH: left ventricular hypertension
Vertical ﬂow indicates order of preference for each condition, but individual boxes list drugs alphabetically and do not suggest order of
use.
Reprinted with permission
Circulation 2011; 123:104-123, #2011 American Heart Association, Inc. All requests to use this material must go via AHA.
AHA website: http://circ.ahajournals.org/cgi/content/short/123/1/104
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tients who are intolerant to rate-control medications
or in whom pharmacological measures fail.1) Rate
control has advantages of low risk of drug-induced
pro-arrhythmia and lower cost, while limitations
include impaired haemodynamics and the need for
long-term anticoagulation.29)
Rhythm-control attempts to restore and/or main-
tain normal sinus rhythm with anti-arrhythmic drugs
or non-pharmacological treatment (Table 1).1,28) Ad-
vantages of anti-arrhythmic therapy include low
initial cost and high eﬃcacy in terms of symptomatic
and haemodynamic improvement, at least initially;
however, these beneﬁts are often oﬀset by high
recurrence rates, high long-term costs, and side
eﬀects such as pro-arrhythmia (e.g., torsades de
pointes), congestive heart failure, organ toxicities
(including neuronal, pulmonary, hepatic, optic neu-
ropathy, and thyroid abnormalities), and increased
mortality in patients with structurally abnormal
hearts.30,31)
Priorities of physicians in Singapore and Malaysia
have hitherto been rate control for permanent AF and
rhythm control for paroxysmal AF.11) Anti-arrhyth-
mic monotherapy is widely prescribed, with amio-
darone preferred in paroxysmal and persistent AF
patients and used more often than ﬂecainide and
propafenone due to their potential pro-arrhythmic
eﬀects, especially in patients with underlying heart
disease. Sotalol and atenolol are also commonly
prescribed for rate/rhythm control in paroxysmal
and persistent AF patients, while in permanent AF
patients, bisoprolol is also used. A minority of
patients in each AF subclass in Singapore (25–30%)
and Malaysia (<20%) progress from ﬁrst- to second-
line treatment, with 10% or fewer receiving third-
line treatment and a similarly low proportion
referred for ablation and other invasive proce-
dures.11)
Paradigm-shift in AF management
Patient safety and well-being are paramount
concerns in AF management. Consequently, key
treatment goals should extend beyond normalising
the ECG pattern and preventing recurrence to
include reducing symptoms, decreasing the risk of
CV and stroke-related morbidity and mortality, and
improving quality of life. These goals necessitate
early detection and treatment of the underlying
causes of AF, for example, thyrotoxicosis, alcohol
consumption, or tachycardia-induced AF.
Novel anti-arrhythmic agents with an approved
indication for AF have been recently introduced and
may potentially enhance patient outcomes compared
to conventional pharmacotherapies. ‘Upstream’ ap-
Table 1 Pharmacological and non-pharmacological interventions to control rate and rhythm and prevent stroke and atrial
remodelling in atrial ﬁbrillation
Therapeutic Strategy Pharmacological Non-pharmacological
Rate control#  Calcium channel blocker  Atrioventricular node ablation
(verapamil, diltiazem) plus ventricular pacing
 -blocker
 Digoxin
 Amiodarone
Rhythm control#  Class 1A (quinidine,  Catheter ablation
disopyramide)  Pacing
 Class 1C (propafenone,  Surgery (Maze procedure,
ﬂecainide) pulmonary vein isolation)
 Class III (sotalol, amiodarone)  Implantable atrial deﬁbrillator
Prevent stroke  Warfarin  Left atrial appendage
 Thrombin inhibitor removal/isolation
 Aspirin
Prevent atrial  Calcium channel blocker
remodelling#  Angiotensin conversion]
enzyme inhibitor
 Angiotensin receptor blocker
# Decide most appropriate therapy based on patient’s proﬁle
 Recommended for all patients
Adapted from American Journal of Cardiology, Vol 85, Prystowsky EN: Management of atrial ﬁbrillation: therapeutic options and
clinical decisions, 3D–11D, # 2000, with permission from Elsevier.
J Arrhythmia Vol 27 No 3 2011
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proaches intended to prevent or attenuate AF-
induced myocardial remodelling are also emerging
as potential treatment modalities.1,25,32)
Stroke prevention
Stroke in AF mainly results from thromboembo-
lism as a consequence of blood stagnating in the left
atrial appendage.33) Most AF patients require appro-
priate thromboprophylaxis, irrespective of whether a
rate- or rhythm-control strategy is used,26) and
generally receive antiplatelet or anticoagulant medi-
cations (Table 1). These agents are recommended for
long-term use in patients at high risk for throm-
boembolism or in those with risk factors for AF
recurrence, for example, underlying structural heart
disease or high CHADS2 (cardiac failure, hyper-
tension, age, diabetes, stroke [doubled]) score.1,32)
Warfarin remains the predominant anticoagulant used
in Singapore and Malaysia;11) newer agents, for
example dabigatran, were only approved very recent-
ly. Left atrial appendage removal/isolation is a non-
pharmacological alternative for stroke prevention.1)
Evidence-based management of atrial ﬁbrillation
Rate-control versus rhythm-control
Studies comparing rate-control and rhythm-con-
trol show no diﬀerence in survival and quality of
life outcomes among AF patients (Table 2).34) Meta-
analysis of ﬁve trials (n ¼ 5;239), detected no
signiﬁcant diﬀerence in all-cause mortality between
rate- and rhythm-control groups (13% vs. 14.6%;
P ¼ 0:09) and rate-control plus anticoagulation
appeared at least equivalent to maintaining sinus
rhythm with anti-arrhythmic agents in reducing the
rate of ischaemic stroke (3.5% vs. 3.9%; P ¼
0:30).35) Therefore, decisions on the most appropri-
ate approach to AF therapy should be individualised
based on patient circumstances and preferences.
Pharmacological rate control
Rate control alone may be suitable for patients
who are asymptomatic or have relatively few
symptoms, and is a preferred option in patients with
AF of longer than 12 months duration, left atrial
diameter greater than six centimetres, or those at
greater risk of pro-arrhythmia.1) The eﬃcacy of rate
control pharmacotherapy is approximately 80%.36)
Non-dihydropyridine calcium channel blockers
(CCBs) are eﬀective for acute and chronic rate
control in AF. During chronic treatment, beta-block-
ers have also been shown to be eﬀective and safe
compared to placebo and digoxin.32) The United
Kingdom National Institute for Health and Clinical
Excellence (NICE) guidelines on the management of
AF (2006), recommend beta-blockers or rate-limit-
ing CCBs as preferred initial monotherapy for
pharmacological rate control in all patients.26) Al-
though digoxin monotherapy reduces heart rate by
approximately 4–21 bpm versus placebo at rest, it is
not eﬀective during exercise,1,37) and should there-
fore only be considered as monotherapy in sedentary
patients. NICE recommends using CCBs plus digox-
in if additional rate control at rest or during exercise
is needed and in cases where rate control with
combination therapy is inadequate, to use other
drugs such as amiodarone or refer for specialist
investigation.26)
Dronaderone
A new rate-control agent for AF is dronaderone
(sanoﬁ-aventis), which is a non-iodinated amiodar-
one-derived multichannel blocker that has an elec-
trophysiological proﬁle similar to its precursor and
has both rate-control and rhythm control activities.
In the Eﬃcacy and Safety of Dronedarone for the
Control of Ventricular Rate During AF (ERATO)
trial, 14 days of treatment with dronedarone added to
standard therapy (including thromboprophylaxis)
signiﬁcantly reduced mean 24-hour ventricular rate
by 11.7 bpm versus placebo in patients with perma-
nent AF (P < 0:0001), which was sustained through
6-months.38)
Pharmacological rhythm control
Pharmacological or electrical cardioversion is
performed as part of a rhythm-control strategy and
should be attempted in patients with signiﬁcant AF
symptoms despite rate control, reasonable potential
for maintaining sinus rhythm, acute haemodynamic
compromise, or recurrent thromboembolism despite
anticoagulation.1) Pharmacological or electrical car-
dioversion is eﬀective in up to 90% of AF patients.39)
NICE recommends using a Class IC anti-arrhyth-
mic (e.g., propafenone or ﬂecainide) for pharmaco-
logical cardioversion in patients without structural
heart disease, but amiodarone if structural heart
disease is present.26) Continuous use of anti-arrhyth-
mic drugs in paroxysmal AF with infrequent (once
per year to every few months) recurrences may not
be justiﬁed relative to their toxicity. In such cases,
especially in the absence of structural heart disease,
outpatient pulse treatment with oral propafenone or
ﬂecainide may be attempted.32) In a study of recent-
onset AF patients with no or minimal heart disease,
self-administration of propafenone or ﬂecainide
successfully controlled over 90% of episodes within
2 hours;40) however, 7% of patients reported adverse
J Arrhythmia Vol 27 No 3 2011
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eﬀects during one or more arrhythmic episodes,
including a case of atrial ﬂutter with rapid con-
duction, indicating that close monitoring is neces-
sary, especially following the ﬁrst treatment.
Maintenance of sinus rhythm is necessary after
cardioversion and may contribute to reduced mortal-
ity and morbidity. In the AF Follow-up Investigation
of Rhythm Management (AFFIRM) study, which
compared rate-control and rhythm-control pharma-
cotherapies, patients in sinus rhythm at the end of the
study across the diﬀerent treatment arms had 47%
reduced risk of mortality compared to those in AF.41)
Overall, use of anti-arrhythmic drugs approximately
doubles the likelihood of maintaining sinus
rhythm.42) Meta-analysis of 44 randomised control-
led trials, suggests that anti-arrhythmic agents
signiﬁcantly reduce the rate of recurrent AF com-
pared to placebo or no treatment, with annual
number needed to treat (NNT) between two and
nine. However, withdrawal due to side eﬀects was
frequent and Class IA anti-arrhythmic agents were
associated with increased mortality.43)
Available data suggest that amiodarone
(NNT ¼ 3) is more eﬀective than either ﬂecainide
and propafenone (NNT ¼ 4), sotalol (NNT ¼ 8), or
placebo in long-term maintenance of sinus rhythm in
patients with paroxysmal or persistent AF.43–47) In
the Sotalol Amiodarone AF Eﬃcacy Trial (SAFE-
T), amiodarone was signiﬁcantly superior to sotalol
in maintaining sinus rhythm, but both drugs showed
similar eﬃcacy in patients with ischaemic heart
disease.48) Post-hoc analysis of AFFIRM patients
treated with rhythm-control, showed amiodarone to
be signiﬁcantly more eﬀective than either sotalol or
Class I agents in achieving sinus rhythm at 1 year
(P  0:002).45) In a prospective multicenter trial,
low-dose amiodarone was more eﬃcacious than
sotalol or propafenone in maintaining sinus rhythm,
with an AF recurrence rate of 35% versus 63% after
mean follow-up of 16 months; however, cardiac and
non-cardiac adverse events requiring discontinuation
of therapy occurred in 18% of patients receiving
amiodarone compared to 11% treated with sotalol
or propafenone.44) Another post-hoc analysis of
AFFIRM showed that mortality and CV hospital-
isation were signiﬁcantly more frequent in those who
received amiodarone as the primary therapy than
among rate-control patients (P < 0:0001).49)
In light of such ﬁndings, the latest thinking in anti-
arrhythmic therapy for recurrent AF advocates a
stepwise, safety-ﬁrst approach, in which safer but
possibly less eﬃcacious medications are tried before
resorting to more potent but less-safe drugs if
initial therapy fails. For this reason, amiodarone is
often reserved for second-line or third-line therapy
(Figure 2),25) because despite being more potent and
eﬀective than other current anti-arrhythmic agents, it
is associated with a relatively high incidence of
potentially severe cardiac and extracardiac adverse
eﬀects.
Dronaderone
In randomised placebo-controlled trials, dronedar-
one was signiﬁcantly more eﬀective in maintaining
sinus rhythm and controlling ventricular rate during
recurrences of AF.50) In the context of rhythm
control, dronedarone has been shown to signiﬁcantly
reduce CV mortality, arrhythmic death, stroke and
hospitalisation relative to placebo,51,52) and is the
ﬁrst anti-arrhythmic drug shown to reduce CV
hospitalisations and the risk of stroke in AF patients.
There are no comparative data on the relative impact
of other anti-arrhythmic agents on similar AF out-
comes.
In a placebo-controlled, double-blind, parallel arm
trial to assess the eﬃcacy of dronedarone (ATHENA)
in 4,628 patients with paroxysmal or persistent AF,
adding dronedarone to standard therapy (including
rate control, and/or antithrombotic therapy and/or
other CV agents) signiﬁcantly decreased the risk of
hospitalisation due to CV events or death from any
cause by 24% versus placebo (Figure 3a). Death from
CV causes occurred in 29% fewer patients in the
dronaderone arm (63) compared to placebo (90)
(Figure 3b).51) Post-hoc analysis also suggested a sig-
niﬁcant decrease in the risk of stroke with dronedar-
one versus placebo (P ¼ 0:027).52) Based on such
data, the United States Food and Drug Administration
approved dronaderone for treating AF.53)
In ATHENA, adverse events occurring signiﬁ-
cantly more frequently with dronedarone than
placebo included bradycardia, QT-interval prolon-
gation, diarrhoea, nausea, rash, and increased serum
creatinine level; no signiﬁcant increases in the rates
of thyroid or pulmonary disorders were observed.
These observations indicate that dronedarone has a
much safer and more benign side-eﬀect proﬁle than
amiodarone. Preliminary data from a trial of eﬃcacy
and safety of dronedarone versus amiodarone for
mainting of sinus rhythm in patients with AF
(DIONYSOS)54) and an indirect meta-analysis com-
paring amiodarone with dronedarone55) show that
although amiodarone is more eﬀective than drone-
darone in maintaining sinus rhythm, dronedarone is
associated with fewer adverse eﬀects and premature
study-drug discontinuations. This unique safety and
eﬃcacy proﬁle suggests an important role for
dronedarone as a ﬁrst-line AF therapy.32)
Omar R AF in SE Asia: Trends & Prospects
177
Non-pharmacological therapy for atrial ﬁbrillation
Healthier lifestyle
Recent research shows that avoiding unhealthy
behaviours and adopting a healthier lifestyle to
minimise the adverse eﬀects of CV risk factors such
as hypertension, smoking, diabetes and excess body-
weight, could potentially more than halve the burden
of AF.56)
Electrical cardioversion
In certain circumstances, for example, younger
patients without structural heart disease and tachy-
cardia-induced cardiomyopathy associated with AF,
non-pharmacological approaches may be preferred
to life-long drug therapy. Electrical cardioversion,
for instance, may be used either alone or in
combination with pharmacotherapy and has an
80% to 90% conversion rate; however, it requires
a
b
Figure 3 (a) ATHENA: Cumulative incidence of cardiovascular hospitalisation or death from any cause
(primary endpoint). (b) ATHENA: Cumulative incidence of cardiovascular mortality (secondary endpoint)
bid: twice-daily administration
Standard therapy may have included rate control agents (beta-blockers, and/or Calcium channel antagonist and/or
digoxin) and/or anti-thrombotic therapy (vitamin K antagonists and/or aspirin and other antiplatelet therapies)
and/or other cardiovascular agents such as angiotensin conversion enzyme inhibitors, angiotensin receptor blockers
and statins.
Hohnloser SH, et al: Eﬀect of dronedarone on cardiovascular events in atrial ﬁbrillation. N Engl J Med 2009; 360:
668–678. Reproduced with permission from Massachusetts Medical Society # 2009
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conscious sedation or anaesthesia as well as anti-
coagulation for 4 weeks pre- and post-treatment in
AF episodes longer than 48 hours.32) In case of
concern about successfully restoring sinus rhythm
(such as previous failure to cardiovert or early
recurrence of AF), concomitant anti-arrhythmic
agents may increase the success of electrical cardio-
version.1) Between 1997 and 1999, the National
Heart Centre in Singapore performed 55 cardiover-
sions for persistent AF; 80% were successful in
restoring sinus rhythm and 5% achieved transient
restoration. Successfully cardioverted patients had
signiﬁcantly lower left atrial size than those in whom
cardioversion was unsuccessful (42 11mm vs.
51 11mm; P ¼ 0:05), and 70% remained in sinus
rhythm during follow-up.39)
Pacing therapy
Pacing with atrioventricular (AV) node ablation
may beneﬁt patients with poorly-tolerated AF that is
refractory to drug treatment. Achieving rate-control
requires AV junction ablation; hence, permanent
anti-bradycardia pacing is necessary.57) Pacing de-
vices may also help to maintain sinus rhythm and
have been shown to be eﬀective mainly in brady-
cardia-induced AF, including sick-sinus syndrome
and its brady-tachy variant. Techniques proposed for
suppressing AF include: standard atrial pacing;
alternative single-site atrial pacing; multi-site atrial
pacing; algorithms to increase the frequency of atrial
pacing; anti-tachycardia atrial pacing for termination
of organised AF or atrial ﬂutter; inter-atrial septal or
Bachmann bundle pacing; combined prevention and
termination algorithms; ventricular and biventricular
pacing; and hybrid approaches (pacing devices with
medications or ablation).58)
Emerging evidence indicates that excessive right
ventricular pacing is deleterious and increases AF,
heart failure, and possibly mortality. Therefore,
physiological pacing with minimisation of right
ventricular pacing is desirable.59) Trials suggest that
in patients with symptomatic bradycardia, the risk of
AF is lower with atrial than ventricular pacing.60)
In patients with sinus node dysfunction and normal
AV conduction, data support atrial or dual-chamber
pacing rather than ventricular pacing for preventing
or delaying progression of AF.61,62) Studies compar-
ing single-site with dual-site or multi-site atrial
pacing in recurrent paroxysmal AF show modest and
non-signiﬁcant beneﬁt of dual/multi-site pacing in
time to ﬁrst AF and frequency of AF.63,64) However,
additional beneﬁts may be obtained by using
particular pacing sites, speciﬁc pacing algorithms
designed to target potential AF triggers, and pace-
termination of atrial tachycardia. Investigations are
currently underway to determine whether minimis-
ing the detrimental eﬀects of right ventricular apical
pacing could further enhance the beneﬁts of AV
synchronous pacing.65)
Implantable atrial debrillators
The success of implantable ventricular deﬁbrilla-
tors in relieving recurrent ventricular tachycardia
prompted the development of implantable atrial
deﬁbrillators that provide reproducible detection
and termination of AF with low-energy shocks,66)
with the aim of achieving internal cardioversion of
AF. In preliminary studies, implantable atrial deﬁb-
rillators have been both eﬀective and safe for
terminating AF in patients without signiﬁcant struc-
tural heart disease.67–69) Nevertheless, frequent ar-
rhythmia recurrences and patient intolerance to
repeated cardioversion shocks remain major limita-
tions of these devices.70)
Catheter ablation
Radiofrequency catheter ablation of the AV node
along with ventricular pacemaker implantation can
improve cardiac performance in AF patients with
suboptimal pharmacological rate control. Alterna-
tively, catheter-based radiofrequency modiﬁcation of
AV node conduction properties may reduce ventric-
ular rate and AF-related symptoms without any
requirement for permanent pacing;1) however, this
procedure is associated with recurrence and AV
node ablation and pacemaker implantation appear
more eﬀective. In a study of 44 patients with
drug-resistant chronic AF, complete AV block was
achieved in all patients undergoing AV node
ablation with permanent ventricular pacemaker
implantation (n ¼ 22), while only 32% of patients
undergoing AV node modiﬁcation had permanent
slowing of the ventricular rate. Patients undergoing
AV node ablation with pacemaker implantation
also experienced a signiﬁcant improvement in
ejection fraction (P < 0:01) and quality of life scores
(P < 0:01) post-ablation relative to baseline. In
contrast, there was no signiﬁcant change in ejection
fraction or quality of life with AV node modiﬁca-
tion.71)
Catheter ablation aimed at permanently curing AF
has become increasingly common and is recom-
mended in highly symptomatic young patients with
focal AF without severe heart disease. Techniques
include: catheter ablation of the triggering focus;
three-dimensional guided left atrial circumferential
ablation with pulmonary vein isolation; lasso-guided
ostial electrical disconnection of pulmonary veins;
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ablation guided by three-dimensional non-contact
electroanatomical mapping; catheter ablation target-
ing complex fractionated atrial electrograms; and a
combination of two or more strategies in the same
individual.72) No speciﬁc technique appears to be
superior and the speciﬁc technique depends on the
type of AF and underlying heart disease. In a
heterogenous patient population (n ¼ 16;309) under-
going treatment at electrophysiology laboratories
worldwide, with diﬀerent techniques and varying
investigator experience, catheter ablation was cura-
tive in an average of 70% of patients without
concomitant anti-arrhythmic agents and in a further
10% with the use of (formerly ineﬀective) anti-
arrhythmic agents after 18 months follow-up. The
overall incidence of major complications (including
death, stroke, transient ischaemic attacks, pericardial
tamponade, pulmonary vein stenosis, atrio-oesopha-
geal ﬁstula, and atypical atrial ﬂutter) was approx-
imately 4.5%.72) Catheter ablation of AF is a rapidly
evolving technique, and these results suggest an
increase in the success rate of catheter ablation
therapy coupled with a reduction in major compli-
cations compared to similar studies conducted in the
past.73) Meta-analyses of studies performed mostly in
patients with paroxysmal AF, that compared anti-
arrhythmic medication and catheter ablation, have
demonstrated superior rhythm control following
catheter ablation.74,75) However, most such studies
included patients already resistant to anti-arrhythmic
drug treatment and had relatively short follow-up
periods. Long-term follow-up studies indicate that
while sinus rhythm is better preserved compared to
anti-arrhythmic drugs, late recurrences of AF are not
uncommon with catheter ablation.76) Considerable
operator experience and technical skill are needed
for ablation of AF, and this should be considered
when contemplating a complex ablation procedure in
a patient with symptomatic AF.
Surgical ablation
Surgery for AF has played an important role in
selected symptomatic AF patients, especially as an
adjunct to coronary bypass or valve repair surgery.
Surgical procedures for AF include the conventional
‘cut and sew’ Maze procedure, pulmonary vein
isolation, and left atrial linear ablation. Maze III, has
become the gold standard to which other surgical
procedures for AF are compared.77) A 10-year
outcome analysis of AF patients (n ¼ 335) under-
going the standard Maze procedure at experienced
surgical centres, indicated that, at last follow-up
(mean, 42 6 months), 88% of the patients were
AF-free.78)
Surgical pulmonary vein isolation is eﬀective in
restoring sinus rhythm in permanent AF associated
with mitral valve disease. In a case series (n ¼ 50) of
box isolations of all four pulmonary veins using
epicardial microwave energy performed totally
endoscopically on the beating heart, 79.5% of
patients were in normal sinus rhythm at last
follow-up (mean, 7.6 months).79)
Due to the complexity and technical diﬃculty
of the Maze procedure, attempts have been made to
simplify the operation by replacing the traditional
‘cut-and-sew’ incisions with linear lines of ablation
created using a variety of energy sources.80) Ex-
cellent results have been reported with radiofre-
quency ablation-assisted Maze procedures, with over
90% of patients remaining symptom free after one
year of treatment.81,82)
The advent of ablation technology has simpliﬁed
the surgical treatment of AF by allowing it to be
performed through limited access incisions. While
few patients have been candidates for a stand-alone
surgical procedure to cure AF, minimally-invasive
approaches in development could expand the indi-
cations for stand-alone surgery for AF in the future.
Prevention of thromboembolism
Pooled analyses from randomised trials demon-
strate that oral anticoagulation therapy with vitamin
K antagonists (e.g., warfarin) reduces the risk of
stroke by 68% compared to 21% with aspirin.83)
The Birmingham Atrial Fibrillation Treatment of
the Aged (BAFTA) study showed that vitamin K
antagonism reduced the occurrence of fatal or
disabling stroke, intracranial haemorrhage, and clin-
ically signiﬁcant arterial embolism by 52% com-
pared to aspirin 75mg daily; there was no diﬀerence
in the risk of serious bleeding complications.84) In
the Warfarin versus Aspirin for Stroke Prevention in
Octogenarians with AF (WASPO) trial, signiﬁcantly
more adverse events, including serious bleeding,
were observed with aspirin than with warfarin (33%
vs. 6%; P ¼ 0:002).85) In the AF Clopidogrel Trial
with Irbesartan for Prevention of Vascular Events-
Warfarin arm (ACTIVE-W) trial, anticoagulation
therapy was superior to the combination of clopi-
dogrel and aspirin, with no diﬀerence in bleeding
events between treatment arms.86) Thus, current
evidence supports the use of warfarin in patients
with AF who are at risk of stroke; however, the
narrow therapeutic index and a high risk/beneﬁt
ratio of warfarin necessitate close and long-term
monitoring. Guidelines in the US87) and UK88)
recommend a target international normalised ratio
(INR) range of two to three for warfarin therapy;
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however, Japanese and Chinese data indicate
that Asians may require lower INR values than
Caucasians (e.g., 1.5 to 2.5) for anticoagulation.89,90)
Combination therapy with warfarin and antiplatelet
agents has been evaluated; however, no beneﬁcial
eﬀect with regard to ischaemic stroke or vascular
events was observed, on the contrary, additional
bleeding was evident.1)
Non-pharmacological approaches to thrombo-
prophylaxis
Removal or closure of the left atrial appendage,
which is considered to be the main site of atrial
thrombogenesis, is performed to reduce the develop-
ment of atrial thrombi and stroke in AF patients with
contraindications to long-term anticoagulation ther-
apy. In a trial comparing the eﬃcacy and safety of
percutaneous closure of the left atrial appendage for
prevention of stroke with warfarin treatment in AF
patients (n ¼ 707), the primary composite eﬃcacy
endpoint of stroke, CV death, and systemic embo-
lism was non-inferior to that of warfarin.91) There
was a higher rate of adverse events in the inter-
vention group than in control subjects, due mainly to
procedural complications. In addition to direct
surgical amputation or truncation of the left atrial
appendage, several methods are under development
to achieve this via intravascular catheters or trans-
pericardial approaches.92)
Upstream therapies in atrial ﬁbrillation
Upstream modulation of certain AF risk factors to
produce downstream eﬀects including reduced like-
lihood of subsequent development of AF has been
investigated with agents including angiotensin con-
version enzyme inhibitors, angiotensin receptor
blockers, aldosterone antagonists, HMG-CoA reduc-
tase inhibitors (statins), corticosteroids and n-3
polyunsaturated fatty acids. However, evidence for
prevention of atrial remodelling from early phase
trials remains equivocal and further large-scale
investigations with adequately deﬁned endpoints
are needed.1)
Management of atrial ﬁbrillation—Evidence
gaps
Our review of the management of AF suggests
that signiﬁcant evidence gaps exist, particularly in
Asian populations; comprehensive epidemiological
data from Asian countries, including Singapore and
Malaysia, are lacking. Although the extent of AF in
these countries is uncertain, it is likely to have been
underestimated. More robust data are needed to
support the case that AF is a serious public health
problem and for including AF metrics (e.g., ECG
screening) in national health surveys.
Although clinical trial data on various AF treat-
ment strategies are promising, it remains to be
determined how the results will translate into real-
life practice and whether or not there may be
diﬀerences in outcomes between Caucasians and
other racial groups. Most current evidence on
strategies to treat AF derives from Caucasians aged
65 years and above who were enrolled into clinical
studies according to strict inclusion and exclusion
criteria. Evidence of beneﬁts of pharmacological
therapy in patient populations outside of clinical
trials, for example, younger patients with minimal or
no underlying heart disease, who are more likely to
beneﬁt from surgery, is lacking.
Addressing challenges and unmet needs
AF imposes a signiﬁcant burden on healthcare
systems and societies and is too prevalent to ignore.
There is an urgent need to engage key stakeholders,
including healthcare funding authorities, policymak-
ers, patients as well as primary care physicians,
cardiologists, and internists in the AF care cycle. The
biggest stakeholders are the primary care physicians
and general physicians at the forefront of screening,
diagnosis, risk stratiﬁcation, counselling and referral
of AF patients to specialist centres.
As the AF management paradigm shifts from a
traditional focus on rate and rhythm control to
normalise ECG patterns and prevent recurrence,
towards prioritising symptom reduction, health-re-
lated quality of life, and reducing CV and cerebro-
vascular morbidity and mortality, the greatest chal-
lenge is to realign physicians’ mindset with this new
thinking. AF is not a single disease, is complex to
treat and requires individualised therapy according
to patients’ symptoms and risk proﬁles. Lack of
awareness of the impact and consequences of AF
among physicians, particularly in the primary care
setting, is common, leading to low detection rates (as
AF is frequently asymptomatic).
Early detection, including that of asymptomatic
disease and treatment of AF is important because of
the risk of serious complications, especially stroke.
Stroke prevention is the biggest issue in AF, as stroke
rather than AF itself is the main cause of mortality;
however, stroke risk is seldom addressed in primary
care. For this reason, there is an urgent need to raise
awareness among physicians that AF increases the
risk of stroke irrespective of symptom severity, and
for continuing medical education on the importance
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of stroke prophylaxis based on proper risk stratiﬁca-
tion (e.g., CHADS2 and CHA2DS2VASc scores)
93)
and use of anticoagulation therapy. Oral anticoagu-
lant therapy remains underused in AF.94,95) Foremost
regarding the underuse of warfarin is the lack of
physician (and patient) awareness about its risk/
beneﬁt proﬁle. Convincing physicians to start war-
farin therapy and achieving a recommended ther-
apeutic INR range are important obstacles to meeting
current challenges in AF management.
Lack of patient education in primary care is also
an important issue. Improving patient awareness and
proactive provision of information to patients need
to be targeted through concerted eﬀorts by both the
physician community and wider society. Treatment
compliance is also an important aspect of AF care, as
all AF patients are at increased risk of thrombotic
events. Therefore, educating patients that they are at
increased risk of stroke and CV events, even though
they may not feel unwell, and ensuring compliance
with warfarin therapy are imperative to reducing AF-
associated morbidity and mortality.
An ideal anti-atrial ﬁbrillation drug?
Enhancing the capability to revert to and maintain
sinus rhythm may beneﬁt highly symptomatic
patients. Currently, rhythm-control is limited by the
drugs available. In the survey of specialists from
Singapore and Malaysia, a majority expressed con-
cerns about the limitations of current medications,
including low eﬃcacy (e.g., with regard to con-
version to sinus rhythm, sinus rhythm maintenance,
and prevention of recurrence), adverse side eﬀects
(e.g., pro-arrhythmia), toxicity, and drug interac-
tions.11) However, most respondents were aware of
new anti-arrhythmic drugs and anticipated reduced
usage of amiodarone in the future due to the
availability of safer alternatives.11)
In principle, an ideal anti-AF drug should be well-
tolerated, eﬃcacious (i.e., should provide relief of
AF symptoms and reduce morbidity, mortality, and
healthcare utilisation), cost-eﬀective with once-daily
administration (to improve compliance), and have a
favourable safety proﬁle relative to the current
options (e.g., no serious side eﬀects and minimal
drug interactions). The perfect anti-arrhythmic agent
is not yet available and the search for new therapies
with better safety and eﬃcacy proﬁles continues.
Conclusions
A paradigm shift in the management of AF, from
a focus on rate and rhythm control towards improv-
ing quality of life and reducing adverse CV and
cerebrovascular outcomes, is needed, with patient
safety assuming overriding priority. Emerging thera-
pies have the potential to overcome certain limita-
tions of established approaches to AF management.
It is our hope that this review of the absolute and
relative beneﬁts and risks of alternative therapeutic
strategies will provide helpful insights that help
fellow physicians to better understand current stand-
ards and gaps in patient care and thereby enhance the
eﬀectiveness of care and address unmet needs to
improve patient outcomes.
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